A new approach to blood pumping
Life-saving flow. A gentler path for blood.
Levanta Flow is developing a magnetic liquid-wall blood pump for extracorporeal life support, designed to reduce blood trauma.
Clinical need
Blood flow and compatibility
The clinical challenge. ECMO temporarily supports the heart and/or lungs. Pumping blood outside the body can damage blood components, with solid surfaces and conventional pump impellers contributing to this challenge.
Our development goal is to reduce mechanical blood trauma while delivering the flow and pressure required for extracorporeal life support.

Technology
A liquid wall. A magnetic drive.
A liquid-tube platform designed to change the blood path and build toward ECMO integration.
Change the blood path
A magnetically confined ferrofluid forms a liquid-in-liquid channel, reducing direct interaction with solid walls in the pumping region.
Move blood magnetically
Magnetic actuation deforms the channel to move blood without a conventional impeller contacting it.
Build toward integration
The first product concept combines a controller and sterile single-use pump set with an OEM oxygenator strategy.
Early evidence and scope
One platform for adult ECMO
Preliminary comparative blood-loop testing of an engineering prototype reported 30% lower haemolysis. A 48-hour blood-loop evaluation also showed preservation of multimeric von Willebrand factor.
Laboratory findings
Ex vivo closed loop human blood recirculation demonstrates clear benefit.
Technical scope
Controller plus sterile single-use liquid-tube pump set, initially targeting adult ECMO.
Clinical strategy
One technical platform targets VV and VA support, with an initial clinical strategy focused on VV and a pathway toward VA.
Development stage
First in-animal study on-going with proof of concept expected late 2027.
Connect
Help shape the platform
We welcome investors, co-development partners, and ECMO clinicians and KOLs to discuss the technology, development needs, and future evaluation priorities.
Contact Levanta Flow
Contact the team about investment, co-development, clinician and KOL collaboration, or general inquiries.
